

Claims 1-23 have been canceled without prejudice to Applicants' right to pursue the subject matter of the canceled claims in subsequent applications. New Claims 24-70, directed to the elected subject matter, have been added. A copy of the pending claims is attached hereto as Exhibit A. Support in the specification for new Claims 24-70 can be found throughout, see, *e.g.*, page 10, line 22 to page 13, line 3 and page 70, line 10 to page 77, line 23. Applicants assert that no new subject matter, as defined in 35 U.S.C. § 132, has been added with the addition of new Claims 24-70.

Entry of the amendments and remarks made herein is respectfully requested.

Respectfully submitted,

*By: Jennifer J. Chheda*  
*Reg No. 46,617*

Date January 24, 2001

*Laura A. Coruzzi* 30,742  
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosure

## **EXHIBIT A**

### **PENDING CLAIMS UPON ENTRY OF THE INSTANT AMENDMENT (FILED JANUARY 24, 2001)**

**APPLICATION SERIAL NO.: 09/503,387  
ATTORNEY DOCKET NO.: 7853-178**

---

24. A composition of substantially purified antibodies, or fragments thereof, which antibodies specifically bind to a polypeptide comprising an amino acid sequence of SEQ ID NO:3 or 16, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as PTA-225.

25. The substantially purified antibody composition of claim 24, wherein the composition contains human antibodies.

26. An isolated non-human antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as PTA-225.

27. The antibody of claim 26 which is a monoclonal antibody.

28. The antibody of claim 27 which is a humanized antibody.

29. A monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as PTA-225.

30. The antibody of claim 29 which is a human antibody.

31. The antibody of claim 29 which is a humanized antibody.
32. The antibody of claim 29 which is a chimeric antibody.
33. The antibody of claim 29 which is conjugated to a therapeutic moiety.
34. The antibody of claim 29 which is linked to a detectable substance.
35. The antibody of claim 34, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.
36. A substantially purified antibody or a fragment thereof which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3 or 16.
37. The antibody of claim 36, wherein the extracellular domain comprises amino acid residues 21 to 269 of SEQ ID NO:3 or amino acid residues 22 to 267 of SEQ ID NO:16.
38. The antibody of claim 36, wherein the extracellular domain comprises an immunoglobulin-like domain.
39. The antibody of claim 38, wherein the immunoglobulin-like domain comprises amino acid residues 48 to 88 or 134 to 180 of SEQ ID NO:3 or amino acid residues 49 to 89 or 135 to 181 of SEQ ID NO:16.
40. The antibody of claim 36 which is a polyclonal antibody.
41. The antibody of claim 36 which is a monoclonal antibody.
42. The antibody of claim 36 which is a chimeric antibody.
43. The antibody of claim 36 which is a humanized antibody.

44. The antibody of claim 36 which is a human antibody.
45. The antibody of claim 36 which is conjugated to a therapeutic moiety.
46. The antibody of claim 36 which is linked to a detectable substance.
47. The antibody of claim 46, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.
48. An antibody Fc region fusion polypeptide comprising an antibody Fc region linked to the amino acid sequence of SEQ ID NO:3 or 16, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as PTA-225, or a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO:3 or 16.
49. The antibody Fc region fusion polypeptide of Claim 48, wherein the amino acid sequence comprises an extracellular domain of the amino acid sequence of SEQ ID NO:3 or 16.
50. The antibody of claim 49, wherein the extracellular domain comprises amino acid residues 21 to 269 of SEQ ID NO:3 or amino acid residues 22 to 267 of SEQ ID NO:16.
51. The antibody of claim 49, wherein the extracellular domain comprises an immunoglobulin-like domain.
52. The antibody of claim 51, wherein the immunoglobulin-like domain comprises amino acid residues 48 to 88 or 134 to 180 of SEQ ID NO:3 or amino acid residues 49 to 89 or 135 to 181 of SEQ ID NO:16.
53. A kit comprising an antibody or fragment thereof as in claim 34, and instructions for use.

54. A kit comprising an antibody or fragment thereof as in claim 46, and instructions for use.

55. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 24, and a pharmaceutically acceptable carrier.

56. A pharmaceutical composition comprising an antibody, or fragment thereof, as in claim 24, a therapeutic moiety, and a pharmaceutically acceptable carrier.

57. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 29, and a pharmaceutically acceptable carrier.

58. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 29, a therapeutic moiety, and a pharmaceutically acceptable carrier.

59. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 33, and a pharmaceutically acceptable carrier.

60. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 33, a therapeutic moiety, and a pharmaceutically acceptable carrier.

61. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 36, and a pharmaceutically acceptable carrier.

62. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 36, a therapeutic moiety, and a pharmaceutically acceptable carrier.

63. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 45, and a pharmaceutically acceptable carrier.

64. A pharmaceutical composition comprising an antibody or fragment thereof as in claim 45, a therapeutic moiety, and a pharmaceutically acceptable carrier.

65. A method of making an antibody that specifically recognizes GPVI, the method comprising:

- a) immunizing a mammal with a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or 16, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as PTA-225, or a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO:3 or 16; and
- b) collecting a sample from the mammal that contains an antibody that specifically recognizes GPVI.

66. The method of claim 65 wherein the polypeptide is recombinantly produced.

67. The method of claim 65 which further comprises purifying antibodies from the sample.

68. The method of claim 65 which further comprises isolating a monoclonal antibody-producing cell from the mammal.

69. The method of claim 68 which further comprises collecting monoclonal antibodies which specifically recognize GPVI from the monoclonal antibody-producing cell.

70. The method of claim 65 wherein the antibody specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3 or 16.